Jéssika de Oliveira Viana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jéssika de Oliveira Viana has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Luciana Scotti
Postgraduate Program in Natural Synthetic and Bioactive Products, Health Sciences Center, Federal University of Paraíba, João Pessoa 58051-900, PB, Brazil, Brazil
5 shared publications - Marcus Tullius Scotti
Universidade Federal da Paraíba, Brazil
5 shared publications - Euzébio Guimarães Barbosa
Universidade Federal do Rio Grande do Norte
4 shared publications - Joilly Nilce Santana Gomes
Department of Pharmacy, Drug Development and Synthesis Laboratory, State University of Paraíba, Campina Grande, 58429-500, Brazil
2 shared publications - Karen Cacilda Weber
Department of Chemistry Federal University of Paraíba João Pessoa Brazil
2 shared publications - Renata Priscila Barros de Menezes
Programa de Pós-graduação em Produtos Naturais e Sintéticos Bioativos (PgPNSB), Universidade Federal da Paraíba, Campus I, Cidade Universitária, João Pessoa, Brasil
2 shared publications
Latest Publications
- Open Access
- 27 April 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (18) , 26569-26583
Structural Basis for Potent Inhibition of Human DHODH by Quinoline-4-carboxylic Acid Derivatives
Quinoline-4-carboxylic acid derivatives are privileged scaffolds in drug discovery, with potential as inhibitors of human dihydroorotate dehydrogenase (HsDHODH), a clinically validated target in cancer and autoimmune diseases. Here, we report computational and structural studies of a series of 6-fluoro-2-(aryl)quinoline-4-carboxylic acids, focusing on their mechanistic basis of inhibition. Molecular docking and molecular dynamics simulations predicted stable binding of compounds 2d and 2e within the HsDHODH binding site. These findings, corroborated by MM-PBSA free energy calculations, suggest a solvent-assisted anchoring mechanism that differs from the binding mode of brequinar. Enzymatic assays confirmed nanomolar potency for compound 2d (IC50 = 27 ± 1 nM), comparable to brequinar, while other derivatives displayed micromolar activity. Crucially, X-ray crystallography of the 2d–HsDHODH complex provided direct structural confirmation of the computationally predicted binding mode. In parallel, ADME modeling predicted a lower Log P for 2d compared with brequinar, pointing to more favorable physicochemical properties. Together, these results establish compound 2d as a potent and drug-like HsDHODH inhibitor and illustrate how integrated computational and structural approaches can elucidate binding determinants of known scaffolds and guide future inhibitor design.
- 27 April 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (18) , 26569-26583
Open AccessStructural Basis for Potent Inhibition of Human DHODH by Quinoline-4-carboxylic Acid Derivatives
Quinoline-4-carboxylic acid derivatives are privileged scaffolds in drug discovery, with potential as inhibitors of human dihydroorotate dehydrogenase (HsDHODH), a clinically validated target in cancer and autoimmune diseases. Here, we report computational and structural studies of a series of 6-fluoro-2-(aryl)quinoline-4-carboxylic acids, focusing on their mechanistic basis of inhibition. Molecular docking and molecular dynamics simulations predicted stable binding of compounds 2d and 2e within the HsDHODH binding site. These findings, corroborated by MM-PBSA free energy calculations, suggest a solvent-assisted anchoring mechanism that differs from the binding mode of brequinar. Enzymatic assays confirmed nanomolar potency for compound 2d (IC50 = 27 ± 1 nM), comparable to brequinar, while other derivatives displayed micromolar activity. Crucially, X-ray crystallography of the 2d–HsDHODH complex provided direct structural confirmation of the computationally predicted binding mode. In parallel, ADME modeling predicted a lower Log P for 2d compared with brequinar, pointing to more favorable physicochemical properties. Together, these results establish compound 2d as a potent and drug-like HsDHODH inhibitor and illustrate how integrated computational and structural approaches can elucidate binding determinants of known scaffolds and guide future inhibitor design.
- Open Access
- 20 August 2025
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 65 (17) , 8901-8910
DynamiSpectra: A Python Software Package and Web Platform for Molecular Dynamics Data Analysis in Computational Biology
Molecular dynamics (MD) simulations generate extensive data sets that demand reliable and reproducible analysis tools. In this study, we present DynamiSpectra, a Python-based software package and web platform designed to automate the descriptive statistical analysis (mean and standard deviation) and visualization of MD trajectories. DynamiSpectra enables streamlined processing of GROMACS-generated files, supporting comparative analyses across multiple simulation replicas without requiring topology file handling or programming expertise. The package performs key structural and dynamic analyses, including RMSD, RMSF, radius of gyration, SASA, hydrogen bonds, salt bridges, secondary structure probability and fraction, principal component analysis, and ligand occupancy maps, producing high-quality graphical outputs with integrated descriptive statistical analysis. Additionally, it supports analyses such as protein-ligand contacts, protein-ligand minimum distance, protein-ligand hydrophobic contacts, inter-residue distance matrices, phi and psi angles, rotamers (χ1 and χ2), ligand dihedral angles, as well as analyses of pressure, temperature, and density within the system. Comparative tests performed against widely used MD analysis packages revealed that the results generated by DynamiSpectra were consistent with those tools. DynamiSpectra stands out for its ability to automate the analysis of multiple replicas, as well as the calculation of mean and standard deviation, which other packages often lack in automation. A use case involving β-amyloid peptide simulations at different temperatures illustrates the platform's capabilities. Furthermore, the DynamiSpectra web interface enables users to upload data, generate interactive plots, and explore results without requiring local installation, thereby promoting accessible and reproducible MD analysis, being another essential distinguishing feature of the tool. The software is freely available via PyPI (https://pypi.org/project/DynamiSpectra/) and GitHub (https://github.com/Conradoou/DynamiSpectra/tree/main). The online web server can be accessed at: https://dynamispectra.onrender.com.
- 20 August 2025
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 65 (17) , 8901-8910
Open AccessDynamiSpectra: A Python Software Package and Web Platform for Molecular Dynamics Data Analysis in Computational Biology
Molecular dynamics (MD) simulations generate extensive data sets that demand reliable and reproducible analysis tools. In this study, we present DynamiSpectra, a Python-based software package and web platform designed to automate the descriptive statistical analysis (mean and standard deviation) and visualization of MD trajectories. DynamiSpectra enables streamlined processing of GROMACS-generated files, supporting comparative analyses across multiple simulation replicas without requiring topology file handling or programming expertise. The package performs key structural and dynamic analyses, including RMSD, RMSF, radius of gyration, SASA, hydrogen bonds, salt bridges, secondary structure probability and fraction, principal component analysis, and ligand occupancy maps, producing high-quality graphical outputs with integrated descriptive statistical analysis. Additionally, it supports analyses such as protein-ligand contacts, protein-ligand minimum distance, protein-ligand hydrophobic contacts, inter-residue distance matrices, phi and psi angles, rotamers (χ1 and χ2), ligand dihedral angles, as well as analyses of pressure, temperature, and density within the system. Comparative tests performed against widely used MD analysis packages revealed that the results generated by DynamiSpectra were consistent with those tools. DynamiSpectra stands out for its ability to automate the analysis of multiple replicas, as well as the calculation of mean and standard deviation, which other packages often lack in automation. A use case involving β-amyloid peptide simulations at different temperatures illustrates the platform's capabilities. Furthermore, the DynamiSpectra web interface enables users to upload data, generate interactive plots, and explore results without requiring local installation, thereby promoting accessible and reproducible MD analysis, being another essential distinguishing feature of the tool. The software is freely available via PyPI (https://pypi.org/project/DynamiSpectra/) and GitHub (https://github.com/Conradoou/DynamiSpectra/tree/main). The online web server can be accessed at: https://dynamispectra.onrender.com.
- Open Access
- 1 July 2025
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 106 (1) , e70152
In Vitro and In Silico Evaluation of Isatin‐Derived Spirooxindoles as Antituberculosis Drug Candidates
Tuberculosis (TB) remains a major global health threat, exacerbated by multidrug‐resistant Mycobacterium tuberculosis (MTB) strains. The development of new anti‐TB agents is crucial. In this study, 17 isatin derivatives synthesized by our research group were evaluated for their in vitro activity against MTB strains and the two most potent compounds were assessed for cytotoxicity. Additionally, molecular docking was performed against 22 MTB protein targets to explore possible mechanisms of action, and ADMET predictions were used to determine pharmacokinetic and pharmacodynamic suitability. Also, we investigated the activity of A15, A16, and A17 against two genetically characterized multidrug‐resistant clinical isolates (PT‐12 and PT‐20). As a result, the compounds A16 and A17 exhibited the highest anti‐TB activity (MIC = 10 μM for both). Inverse molecular docking indicated the enzyme enoyl‐[acyl‐carrier‐protein] reductase as a potential biological target. Cytotoxicity assays confirmed that A16 and A17 were non‐toxic, and ADMET predictions indicated suitable drug‐like properties for anti‐TB therapy. Notably, A16 and A17 showed inhibitory effects against drug‐resistant MTB isolates, with minimum inhibitory concentrations (MICs) ranging from 10 to 20 μM, suggesting their potential to overcome resistance mechanisms linked to mutations in katG and rpoB. These findings highlight A16 and A17 as promising candidates for anti‐TB agents, particularly against multidrug‐resistant strains.
- 1 July 2025
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 106 (1) , e70152
Open AccessIn Vitro and In Silico Evaluation of Isatin‐Derived Spirooxindoles as Antituberculosis Drug Candidates
Tuberculosis (TB) remains a major global health threat, exacerbated by multidrug‐resistant Mycobacterium tuberculosis (MTB) strains. The development of new anti‐TB agents is crucial. In this study, 17 isatin derivatives synthesized by our research group were evaluated for their in vitro activity against MTB strains and the two most potent compounds were assessed for cytotoxicity. Additionally, molecular docking was performed against 22 MTB protein targets to explore possible mechanisms of action, and ADMET predictions were used to determine pharmacokinetic and pharmacodynamic suitability. Also, we investigated the activity of A15, A16, and A17 against two genetically characterized multidrug‐resistant clinical isolates (PT‐12 and PT‐20). As a result, the compounds A16 and A17 exhibited the highest anti‐TB activity (MIC = 10 μM for both). Inverse molecular docking indicated the enzyme enoyl‐[acyl‐carrier‐protein] reductase as a potential biological target. Cytotoxicity assays confirmed that A16 and A17 were non‐toxic, and ADMET predictions indicated suitable drug‐like properties for anti‐TB therapy. Notably, A16 and A17 showed inhibitory effects against drug‐resistant MTB isolates, with minimum inhibitory concentrations (MICs) ranging from 10 to 20 μM, suggesting their potential to overcome resistance mechanisms linked to mutations in katG and rpoB. These findings highlight A16 and A17 as promising candidates for anti‐TB agents, particularly against multidrug‐resistant strains.
- Open Access
- 20 December 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (1) , 306-317
In Silico Structural Insights and Potential Inhibitor Identification Based on the Benzothiazole Core for Targeting Leishmania major Pteridine Reductase 1
Leishmaniasis is reported as the second most common protozoonosis, with the highest prevalence and mortality rate. Among the Leishmania drug targets, Pteridine Reductase 1 of Leishmania major (LmPTR1) proved to be promising because Leishmania is auxotrophic for folates. Thus, this study employed a combination of ligand- and structure-based approaches to screen new benzothiazole compounds as LmPTR1 inhibitor candidates. Initially, a highly predictive quantitative structure-activity relationship (QSAR) model was able to identify the relevant hybrid descriptors, with an accuracy of over 93%. Insights into the mechanism of action indicated Phe113, His241, Leu188, Met183, and Leu226 as key residues. New commercially available compounds were screened using QSAR, docking, and pharmacokinetic properties as filters. Molecular dynamics, non-covalent interactions analysis, and quantum chemical calculation of binding enthalpy demonstrated that the lead compound (ZINC 72229720) forms a stable complex with LmPTR1, indicating it as a new promising LmPTR1 inhibitor.
- 20 December 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (1) , 306-317
Open AccessIn Silico Structural Insights and Potential Inhibitor Identification Based on the Benzothiazole Core for Targeting Leishmania major Pteridine Reductase 1
Leishmaniasis is reported as the second most common protozoonosis, with the highest prevalence and mortality rate. Among the Leishmania drug targets, Pteridine Reductase 1 of Leishmania major (LmPTR1) proved to be promising because Leishmania is auxotrophic for folates. Thus, this study employed a combination of ligand- and structure-based approaches to screen new benzothiazole compounds as LmPTR1 inhibitor candidates. Initially, a highly predictive quantitative structure-activity relationship (QSAR) model was able to identify the relevant hybrid descriptors, with an accuracy of over 93%. Insights into the mechanism of action indicated Phe113, His241, Leu188, Met183, and Leu226 as key residues. New commercially available compounds were screened using QSAR, docking, and pharmacokinetic properties as filters. Molecular dynamics, non-covalent interactions analysis, and quantum chemical calculation of binding enthalpy demonstrated that the lead compound (ZINC 72229720) forms a stable complex with LmPTR1, indicating it as a new promising LmPTR1 inhibitor.
- Open Access
- 1 June 2024
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 24 (11) , 1125-1146
The Power of Molecular Dynamics Simulations and Their Applications to Discover Cysteine Protease Inhibitors
A large family of enzymes with the function of hydrolyzing peptide bonds, called peptidases or cysteine proteases (CPs), are divided into three categories according to the peptide chain involved. CPs catalyze the hydrolysis of amide, ester, thiol ester, and thioester peptide bonds. They can be divided into several groups, such as papain-like (CA), viral chymotrypsin-like CPs (CB), papainlike endopeptidases of RNA viruses (CC), legumain-type caspases (CD), and showing active residues of His, Glu/Asp, Gln, Cys (CE). The catalytic mechanism of CPs is the essential cysteine residue present in the active site. These mechanisms are often studied through computational methods that provide new information about the catalytic mechanism and identify inhibitors. The role of computational methods during drug design and development stages is increasing. Methods in Computer-Aided Drug Design (CADD) accelerate the discovery process, increase the chances of selecting more promising molecules for experimental studies, and can identify critical mechanisms involved in the pathophysiology and molecular pathways of action. Molecular dynamics (MD) simulations are essential in any drug discovery program due to their high capacity for simulating a physiological environment capable of unveiling significant inhibition mechanisms of new compounds against target proteins, especially CPs. Here, a brief approach will be shown on MD simulations and how the studies were applied to identify inhibitors or critical information against cysteine protease from several microorganisms, such as Trypanosoma cruzi (cruzain), Trypanosoma brucei (rhodesain), Plasmodium spp. (falcipain), and SARS-CoV-2 (Mpro). We hope the readers will gain new insights and use our study as a guide for potential compound identifications using MD simulations.
- 1 June 2024
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 24 (11) , 1125-1146
Open AccessThe Power of Molecular Dynamics Simulations and Their Applications to Discover Cysteine Protease Inhibitors
A large family of enzymes with the function of hydrolyzing peptide bonds, called peptidases or cysteine proteases (CPs), are divided into three categories according to the peptide chain involved. CPs catalyze the hydrolysis of amide, ester, thiol ester, and thioester peptide bonds. They can be divided into several groups, such as papain-like (CA), viral chymotrypsin-like CPs (CB), papainlike endopeptidases of RNA viruses (CC), legumain-type caspases (CD), and showing active residues of His, Glu/Asp, Gln, Cys (CE). The catalytic mechanism of CPs is the essential cysteine residue present in the active site. These mechanisms are often studied through computational methods that provide new information about the catalytic mechanism and identify inhibitors. The role of computational methods during drug design and development stages is increasing. Methods in Computer-Aided Drug Design (CADD) accelerate the discovery process, increase the chances of selecting more promising molecules for experimental studies, and can identify critical mechanisms involved in the pathophysiology and molecular pathways of action. Molecular dynamics (MD) simulations are essential in any drug discovery program due to their high capacity for simulating a physiological environment capable of unveiling significant inhibition mechanisms of new compounds against target proteins, especially CPs. Here, a brief approach will be shown on MD simulations and how the studies were applied to identify inhibitors or critical information against cysteine protease from several microorganisms, such as Trypanosoma cruzi (cruzain), Trypanosoma brucei (rhodesain), Plasmodium spp. (falcipain), and SARS-CoV-2 (Mpro). We hope the readers will gain new insights and use our study as a guide for potential compound identifications using MD simulations.
- Open Access
- 5 May 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Scaffold repositioning of spiro-acridine derivatives as fungi chitinase inhibitor by target fishing and in vitro studies
The concept of “one target, one drug, one disease” is not always true, as compounds with previously described therapeutic applications can be useful to treat other maladies. For example, acridine derivatives have several potential therapeutic applications. In this way, identifying new potential targets for available drugs is crucial for the rational management of diseases. Computational methodologies are interesting tools in this field, as they use rational and direct methods. Thus, this study focused on identifying other rational targets for acridine derivatives by employing inverse virtual screening (IVS). This analysis revealed that chitinase enzymes can be potential targets for these compounds. Subsequently, we coupled molecular docking consensus analysis to screen the best chitinase inhibitor among acridine derivatives. We observed that 3 compounds displayed potential enhanced activity as fungal chitinase inhibitors, showing that compound 5 is the most active molecule, with an IC50 of 0.6 ng/µL. In addition, this compound demonstrated a good interaction with the active site of chitinases from Aspergillus fumigatus and Trichoderma harzianum. Additionally, molecular dynamics and free energy demonstrated complex stability for compound 5. Therefore, this study recommends IVS as a powerful tool for drug development. The potential applications are highlighted as this is the first report of spiro-acridine derivatives acting as chitinase inhibitors that can be potentially used as antifungal and antibacterial candidates.
- 5 May 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Open AccessScaffold repositioning of spiro-acridine derivatives as fungi chitinase inhibitor by target fishing and in vitro studies
The concept of “one target, one drug, one disease” is not always true, as compounds with previously described therapeutic applications can be useful to treat other maladies. For example, acridine derivatives have several potential therapeutic applications. In this way, identifying new potential targets for available drugs is crucial for the rational management of diseases. Computational methodologies are interesting tools in this field, as they use rational and direct methods. Thus, this study focused on identifying other rational targets for acridine derivatives by employing inverse virtual screening (IVS). This analysis revealed that chitinase enzymes can be potential targets for these compounds. Subsequently, we coupled molecular docking consensus analysis to screen the best chitinase inhibitor among acridine derivatives. We observed that 3 compounds displayed potential enhanced activity as fungal chitinase inhibitors, showing that compound 5 is the most active molecule, with an IC50 of 0.6 ng/µL. In addition, this compound demonstrated a good interaction with the active site of chitinases from Aspergillus fumigatus and Trichoderma harzianum. Additionally, molecular dynamics and free energy demonstrated complex stability for compound 5. Therefore, this study recommends IVS as a powerful tool for drug development. The potential applications are highlighted as this is the first report of spiro-acridine derivatives acting as chitinase inhibitors that can be potentially used as antifungal and antibacterial candidates.
- Open Access
- 15 January 2022
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 44 (1) , 383-408
Computer-Assisted Discovery of Alkaloids with Schistosomicidal Activity
Schistosomiasis is a chronic parasitic disease caused by trematodes of the genus Schistosoma; it is commonly caused by Schistosoma mansoni, which is transmitted by Bioamphalaria snails. Studies show that more than 200 million people are infected and that more than 90% of them live in Africa. Treatment with praziquantel has the best cost–benefit result on the market. However, hypersensitivity, allergy, and drug resistance are frequently presented after administration. From this perspective, ligand-based and structure-based virtual screening (VS) techniques were combined to select potentially active alkaloids against S. mansoni from an internal dataset (SistematX). A set of molecules with known activity against S. mansoni was selected from the ChEMBL database to create two different models with accuracy greater than 84%, enabling ligand-based VS of the alkaloid bank. Subsequently, structure-based VS was performed through molecular docking using four targets of the parasite. Finally, five consensus hits (i.e., five alkaloids with schistosomicidal potential), were selected. In addition, in silico evaluations of the metabolism, toxicity, and drug-like profile of these five selected alkaloids were carried out. Two of them, namely, 11,12-methylethylenedioxypropoxy and methyl-3-oxo-12-methoxy-n(1)-decarbomethoxy-14,15-didehydrochanofruticosinate, had plausible toxicity, metabolomics, and toxicity profiles. These two alkaloids could serve as starting points for the development of new schistosomicidal compounds based on natural products.
- 15 January 2022
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 44 (1) , 383-408
Open AccessComputer-Assisted Discovery of Alkaloids with Schistosomicidal Activity
Schistosomiasis is a chronic parasitic disease caused by trematodes of the genus Schistosoma; it is commonly caused by Schistosoma mansoni, which is transmitted by Bioamphalaria snails. Studies show that more than 200 million people are infected and that more than 90% of them live in Africa. Treatment with praziquantel has the best cost–benefit result on the market. However, hypersensitivity, allergy, and drug resistance are frequently presented after administration. From this perspective, ligand-based and structure-based virtual screening (VS) techniques were combined to select potentially active alkaloids against S. mansoni from an internal dataset (SistematX). A set of molecules with known activity against S. mansoni was selected from the ChEMBL database to create two different models with accuracy greater than 84%, enabling ligand-based VS of the alkaloid bank. Subsequently, structure-based VS was performed through molecular docking using four targets of the parasite. Finally, five consensus hits (i.e., five alkaloids with schistosomicidal potential), were selected. In addition, in silico evaluations of the metabolism, toxicity, and drug-like profile of these five selected alkaloids were carried out. Two of them, namely, 11,12-methylethylenedioxypropoxy and methyl-3-oxo-12-methoxy-n(1)-decarbomethoxy-14,15-didehydrochanofruticosinate, had plausible toxicity, metabolomics, and toxicity profiles. These two alkaloids could serve as starting points for the development of new schistosomicidal compounds based on natural products.
- Open Access
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Brazilian Oral Research
- Vol. 34, e094
Orofacial antinociceptive activity and anchorage molecular mechanism in silico of geraniol
We aimed to evaluate the orofacial antinociceptive effect of geraniol in mice and its molecular anchorage mechanism. Seven mice per group (probabilistic sample) were treated with geraniol (12.5, 25 and 50 mg/kg, i.p.), morphine (6 mg/kg, i.p.) and vehicle (saline + Tween 80 at 0.2%, i.p.) 30 minutes prior to the beginning of the experiment. Injecting glutamate (25 μM), capsaicin (2.5 μg) and formalin (2%) into the right upper lip (perinasal) of the mouse induced nociception. Behavioral analysis of the animals considered the friction time (in seconds) of the mentioned region using hind or front paws by a researcher blinded to the treatment groups. The statistical analysis was performed blindly, considering α = 5%. The results showed that in the glutamate and capsaicin tests, concentrations of 25 mg/kg and 50 mg/kg presented antinociceptive activity (p < 0.005, power> 80%). In the formalin test, geraniol was able to reduce nociception at a concentration of 50 mg/kg (p < 0.005, power> 80%). In the molecular anchorage study, high values of binding between the evaluated substance and receptors of glutamate were observed (metabotropic glutamate receptor, -87.8501 Kcal/mol; N-methyl-D-aspartate, -86.4451 Kcal/mol; α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid, -85.6755 Kcal/mol). Geraniol presented orofacial antinociceptive activity, probably by interacting with glutamate-related receptors.
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Brazilian Oral Research
- Vol. 34, e094
Open AccessOrofacial antinociceptive activity and anchorage molecular mechanism in silico of geraniol
We aimed to evaluate the orofacial antinociceptive effect of geraniol in mice and its molecular anchorage mechanism. Seven mice per group (probabilistic sample) were treated with geraniol (12.5, 25 and 50 mg/kg, i.p.), morphine (6 mg/kg, i.p.) and vehicle (saline + Tween 80 at 0.2%, i.p.) 30 minutes prior to the beginning of the experiment. Injecting glutamate (25 μM), capsaicin (2.5 μg) and formalin (2%) into the right upper lip (perinasal) of the mouse induced nociception. Behavioral analysis of the animals considered the friction time (in seconds) of the mentioned region using hind or front paws by a researcher blinded to the treatment groups. The statistical analysis was performed blindly, considering α = 5%. The results showed that in the glutamate and capsaicin tests, concentrations of 25 mg/kg and 50 mg/kg presented antinociceptive activity (p < 0.005, power> 80%). In the formalin test, geraniol was able to reduce nociception at a concentration of 50 mg/kg (p < 0.005, power> 80%). In the molecular anchorage study, high values of binding between the evaluated substance and receptors of glutamate were observed (metabotropic glutamate receptor, -87.8501 Kcal/mol; N-methyl-D-aspartate, -86.4451 Kcal/mol; α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid, -85.6755 Kcal/mol). Geraniol presented orofacial antinociceptive activity, probably by interacting with glutamate-related receptors.
- Open Access
- 23 November 2018
- Published by MDPI AG
PROPOSITION IN SILICO OF BENZOIC ANALOGS AGAINST Staphylococcus aureus
The microorganism Staphylococcus aureus is a gram-positive spherical bacteria present in the healthy human body, commonly found in the nostrils and skin. It is responsible for a number of infections such as inflammation in the follicles, contribution to the onset of acne, inflammation in the meninges, cardiovascular inflammation, lung inflammation and others. Benzoic compounds are widely used as drug prototypes for various diseases such as cancer, degenerative diseases, microbiological infections and inflammation, and viral infections. This work aims to propose new benzoic in silico bioactives to combat Staphylococcus aureus. To do this, a series of benzoic acid derivatives were submitted to a prediction model of biological activity developed in the KNIME Analytics Platform 3.6, where the molecules that showed activity in the model were imported into OSIRIS DataWarrior 4.7.3 to predict the risks of cytotoxicity, the calculation of the Lipinski rule violations and the absorption rate (% ABS). For the molecules approved by the virtual screening already commented, the calculation of the energies of interaction between receptor and binder by molecular docking and the analysis of the interactions with the residues of amino acids were carried out, comparing with the interactions of the drugs used as control in this research. As conclusion of this work it was possible to propose bioactive molecules against S. aureus based on the obtained computational data.
- 23 November 2018
- Published by MDPI AG
Open AccessPROPOSITION IN SILICO OF BENZOIC ANALOGS AGAINST Staphylococcus aureus
The microorganism Staphylococcus aureus is a gram-positive spherical bacteria present in the healthy human body, commonly found in the nostrils and skin. It is responsible for a number of infections such as inflammation in the follicles, contribution to the onset of acne, inflammation in the meninges, cardiovascular inflammation, lung inflammation and others. Benzoic compounds are widely used as drug prototypes for various diseases such as cancer, degenerative diseases, microbiological infections and inflammation, and viral infections. This work aims to propose new benzoic in silico bioactives to combat Staphylococcus aureus. To do this, a series of benzoic acid derivatives were submitted to a prediction model of biological activity developed in the KNIME Analytics Platform 3.6, where the molecules that showed activity in the model were imported into OSIRIS DataWarrior 4.7.3 to predict the risks of cytotoxicity, the calculation of the Lipinski rule violations and the absorption rate (% ABS). For the molecules approved by the virtual screening already commented, the calculation of the energies of interaction between receptor and binder by molecular docking and the analysis of the interactions with the residues of amino acids were carried out, comparing with the interactions of the drugs used as control in this research. As conclusion of this work it was possible to propose bioactive molecules against S. aureus based on the obtained computational data.